Article summary
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have released comprehensive guidelines to assist pharmaceutical companies in implementing Shortage Mitigation Plans (SMPs) and Shortage Prevention Plans (SPPs). These measures aim to address the escalating issue of medicine shortages across Europe, exacerbated by the COVID-19 pandemic, which has significantly impacted patient care and treatment availability.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial